TBPH vs. SLRN, ANNX, ANRO, TVTX, TRDA, PEPG, CRBP, BMEA, MRSN, and MREO
Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Acelyrin (SLRN), Annexon (ANNX), Alto Neuroscience (ANRO), Travere Therapeutics (TVTX), Entrada Therapeutics (TRDA), PepGen (PEPG), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), Mersana Therapeutics (MRSN), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical preparations" industry.
Theravance Biopharma (NASDAQ:TBPH) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.
Theravance Biopharma has higher revenue and earnings than Acelyrin. Theravance Biopharma is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Theravance Biopharma received 325 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 63.38% of users gave Theravance Biopharma an outperform vote while only 56.25% of users gave Acelyrin an outperform vote.
Theravance Biopharma currently has a consensus target price of $20.50, suggesting a potential upside of 142.89%. Acelyrin has a consensus target price of $23.67, suggesting a potential upside of 466.19%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Theravance Biopharma.
In the previous week, Theravance Biopharma had 2 more articles in the media than Acelyrin. MarketBeat recorded 3 mentions for Theravance Biopharma and 1 mentions for Acelyrin. Theravance Biopharma's average media sentiment score of 0.96 beat Acelyrin's score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the media.
99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Acelyrin has a net margin of 0.00% compared to Theravance Biopharma's net margin of -96.12%. Theravance Biopharma's return on equity of -19.31% beat Acelyrin's return on equity.
Summary
Theravance Biopharma beats Acelyrin on 12 of the 16 factors compared between the two stocks.
Get Theravance Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theravance Biopharma Competitors List
Related Companies and Tools
